Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial.


BY CARL ZIMMER | NYTimes Health | Disclosure


This post first appeared on Think, please read the originial post: here

Share the post

CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial.

×

Subscribe to Think

Get updates delivered right to your inbox!

Thank you for your subscription

×